1-[(4-fluorophenyl)methyl]-1H-pyrrole-2-carboxylic acid | 406728-86-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 1-[(4-fluorophenyl)methyl]-1H-pyrrole-2-carboxylic acid
• 英文别名: 1-(4-fluorobenzyl)-1H-pyrrole-2-carboxylic acid；N-(4-fluorobenzyl)pyrrole-2-carboxylic acid；1H-Pyrrole-2-carboxylic acid, 1-[(4-fluorophenyl)methyl]-；1-[(4-fluorophenyl)methyl]pyrrole-2-carboxylic acid
• CAS: 406728-86-7
• 化学式: C₁₂H₁₀FNO₂
• mdl: MFCD12181402
• 分子量: 219.215
• InChiKey: PDFAKAUXPIKVFC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  42.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-[(4-fluorophenyl)methyl]-1H-pyrrole-2-carboxylic acid 、 bis(diphenylmethyl) L-tartrate 在 4-二甲氨基吡啶 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 以82%的产率得到bis(diphenylmethyl) 2-(N-(p-fluorobenzyl)-2-pyrroloyl)-L-tartrate
  参考文献：
  名称：

  Design, Synthesis, and Biological Evaluation of Novel Hybrid Dicaffeoyltartaric/Diketo Acid and Tetrazole-Substituted l-Chicoric Acid Analogue Inhibitors of Human Immunodeficiency Virus Type 1 Integrase

  摘要：

  Fourteen analogues of the anti-HIV-1 integrase (IN) inhibitor L-chicoric acid (L-CA) were prepared. Their IC50 values for 3'-end processing and strand transfer against recombinant HIV-1 IN were determined in vitro, and their cell toxicities and EC50 against HIV-1 were measured in cells (ex vivo). Compounds 1-6 are catechol/beta-diketoacid hybrids, the majority of which exhibit submicromolar potency against 3'-end processing and strand transfer, though only with modest antiviral activities. Compounds 7-10 are L-CA/p-fluorobenzylpyrroloyl hybrids, several of which were more potent against strand transfer than 3'-end processing, a phenomenon previously attributed to the beta-diketo acid pharmacophore. Compounds 11-14 are tetrazole bioisosteres of L-CA and its analogues, whose in vitro potencies were comparable to L-CA but with enhanced antiviral potency. The trihydroxyphenyl analogue 14 was 30-fold more potent than L-CA at relatively nontoxic concentrations. These data indicate that L-CA analogues are attractive candidates for development into clinically relevant inhibitors of HIV-1 IN.

  DOI：

  10.1021/jm1010594
• 作为产物：
  描述：

  methyl 1-(4-fluorobenzyl)-1H-pyrrole-2-carboxylate 在 sodium hydroxide 、 盐酸 作用下， 以 甲醇 、 水 为溶剂， 反应 3.0h， 以88%的产率得到1-[(4-fluorophenyl)methyl]-1H-pyrrole-2-carboxylic acid
  参考文献：
  名称：

  Design, Synthesis, and Biological Evaluation of Novel Hybrid Dicaffeoyltartaric/Diketo Acid and Tetrazole-Substituted l-Chicoric Acid Analogue Inhibitors of Human Immunodeficiency Virus Type 1 Integrase

  摘要：

  Fourteen analogues of the anti-HIV-1 integrase (IN) inhibitor L-chicoric acid (L-CA) were prepared. Their IC50 values for 3'-end processing and strand transfer against recombinant HIV-1 IN were determined in vitro, and their cell toxicities and EC50 against HIV-1 were measured in cells (ex vivo). Compounds 1-6 are catechol/beta-diketoacid hybrids, the majority of which exhibit submicromolar potency against 3'-end processing and strand transfer, though only with modest antiviral activities. Compounds 7-10 are L-CA/p-fluorobenzylpyrroloyl hybrids, several of which were more potent against strand transfer than 3'-end processing, a phenomenon previously attributed to the beta-diketo acid pharmacophore. Compounds 11-14 are tetrazole bioisosteres of L-CA and its analogues, whose in vitro potencies were comparable to L-CA but with enhanced antiviral potency. The trihydroxyphenyl analogue 14 was 30-fold more potent than L-CA at relatively nontoxic concentrations. These data indicate that L-CA analogues are attractive candidates for development into clinically relevant inhibitors of HIV-1 IN.

  DOI：

  10.1021/jm1010594

文献信息

• PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS
  申请人：Forma Therapeutics, Inc.

  公开号：US20160185785A1

  公开（公告）日：2016-06-30

  The invention relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: where m, n, X 1 , X 2 , R 1 -R 5 , R 5′ and R 6 are described herein.

  这项发明涉及USP7抑制剂，用于治疗癌症、神经退行性疾病、免疫紊乱、炎症性疾病、心血管疾病、缺血性疾病、病毒感染和疾病、细菌感染和疾病，具有以下结构式： 其中m、n、X1、X2、R1-R5、R5'和R6如本文所述。
• N-heteroaryl indole carboxamides and analogues thereof, for use as glcokinase activators in the treatment of diabetes
  申请人：Lau F. Jesper

  公开号：US20070027140A1

  公开（公告）日：2007-02-01

  This invention relates to compounds that are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial. The compounds are of the general formula (I) wherin A and B are further defined in the application.

  本发明涉及激活葡萄糖激酶的化合物，因此可能对增加葡萄糖激酶活性有益的疾病的管理、治疗、控制或辅助治疗具有用处。这些化合物的一般式为（I）其中A和B在申请中有进一步定义。
• N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES
  申请人：Lau Jesper F.

  公开号：US20110082144A1

  公开（公告）日：2011-04-07

  This invention relates to compounds that are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial. The compounds are of the general formula (I) wherein A and B are further defined in the application.

  本发明涉及一种激活葡萄糖激酶的化合物，因此可能有助于管理、治疗、控制或辅助治疗增加葡萄糖激酶活性有益的疾病。该化合物的一般公式为(I)，其中A和B在申请中有进一步定义。
• N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
  申请人：TransTech Pharma, Inc.

  公开号：US07812043B2

  公开（公告）日：2010-10-12

  This invention relates to compounds that are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial. The compounds are of the general formula (I) wherein A and B are further defined in the application.

  本发明涉及一种激活葡萄糖激酶的化合物，因此可用于治疗、控制或辅助治疗增加葡萄糖激酶活性有益的疾病。该化合物的一般式为(I)，其中A和B在申请中有进一步定义。
• Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors
  申请人：FORMA Therapeutics, Inc.

  公开号：US10377760B2

  公开（公告）日：2019-08-13

  The invention relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: where m, n, X1, X2, R1-R5, R5 and R6 are described herein.

  本发明涉及可用于治疗癌症、神经退行性疾病、免疫性疾病、炎症性疾病、心血管疾病、缺血性疾病、病毒感染和疾病以及细菌感染和疾病的USP7抑制剂，其具有如下式子： 其中 m、n、X1、X2、R1-R5、R5 和 R6 在本文中描述。